Kolbe You have been working at Kalbe for 38 years, and as President Director for 11 years. What has it been like to see the firm transform from a company based in a garage in Tanjung Priok, to the leading pharmaceutical company in the country? From the company’s founding days, there…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual gathering of all 850 members? The committees are important to our community, but we also bring all our members together…
Lloyd Laboratories Ms Balajadia, you founded Lloyd Laboratories in 1989. What was the driving force behind the establishment of the company? Truth is, when we started on our first business venture way back in 1976, we never even thought or planned of one day putting up a manufacturing plant. We were into…
Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…
Bogin Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics industry, I would like to begin please with a brief history of Bogin. What was the market landscape in the…
Association of Innovative Pharmaceutical Manufacturers (AIPM) Hungary - Innovatív Gyógyszergyártók Egyesülete With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But if we first take a step back… Can you explain to our readers what has attracted most of your members to have a presence in the Hungarian market? V.N.I.:…
Bristol-Myers Squibb Brazil Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic diseases for when the UN next addresses the General Assembly in September. What would be your suggestions? If…
Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…
WestHolland Foreign Investment Agency (WFIA) WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the Life Sciences sector. What drives the agency to place so much effort on attracting investments in Life Sciences in the…
Eurofarma Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two areas in Eurofarma? I’ve spent my whole career in marketing, beginning in direct-to-consumer marketing in OTCs. In the 2000s, when…
Takeda Italy Takeda has more than 25 years of history in Italy and reached the 20th position in the Italian market- a striking performance in a context when it is still rare to see Japanese companies being very successful in Europe, with such a different culture. Which main guidelines of the Italian…
Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…
See our Cookie Privacy Policy Here
